Advertisement

BioDrugs

, Volume 33, Issue 1, pp 9–14 | Cite as

Current Ebola Virus Vaccine Progress

  • Andrea Marzi
  • Chad E. MireEmail author
Leading Article

Abstract

Over 40 years since the discovery of Ebola virus, the anti-Ebola virus vaccine efforts of the past 2 decades have culminated in over 12 different vaccine candidates that have been placed into a number of clinical trial phases, past and present. Of these 12 vaccines, four candidates are up to or in phase II clinical trials, and only one has completed the phase III clinical trial stage. While remarkable progress toward a national regulatory agency-approved vaccine for Ebola virus has been made, there remain unanswered questions on issues such as, but not limited to, vaccine protective immunity and duration of that immunity, and the appropriate vaccination strategy for those at risk of Ebola virus infection.

Notes

Acknowledgements

We thank Heinz Feldmann for his critical review of the manuscript.

Compliance with Ethical Standards

Funding

This article was funded by the Division of Intramural Research, NIAID, NIH and UC7 AI094660 to UTMB for BSL-4 operations.

Conflict of interest

Andrea Marzi and Chad Mire have no conflicts of interests.

References

  1. 1.
    Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature. 2000;408:605–9.CrossRefGoogle Scholar
  2. 2.
    Mire CE, Geisbert TW, Feldmann H, Marzi A. Ebola virus vaccines—reality or fiction? Expert Rev Vacc. 2016;15:1421–30.CrossRefGoogle Scholar
  3. 3.
    Marzi A, Robertson SJ, Haddock E, EBOLA VACCINE, et al. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science. 2015;349:739–42.CrossRefGoogle Scholar
  4. 4.
    Ledgerwood JE, Costner P, Desai N, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine. 2010;29:304–13.CrossRefGoogle Scholar
  5. 5.
    Martin JE, Sullivan NJ, Enama ME, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vacc Immunol CVI. 2006;13:1267–77.CrossRefGoogle Scholar
  6. 6.
    Branswell H. As foreign powers approve Ebola vaccines, U.S. drug makers lag in development pipeline. https://www.statnews.com/2017/12/08/ebola-vaccine-development/.
  7. 7.
    Feldmann H, Sanchez A, Geisbert TW. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott Williams & Wilkins; 2013. p. 923–56.Google Scholar
  8. 8.
    WHO. Ebola situation report, 30 March 2016. Geneva: World Health Organization; 2016.Google Scholar
  9. 9.
    Sullivan NJ, Martin JE, Graham BS, Nabel GJ. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol. 2009;7:393–400.CrossRefGoogle Scholar
  10. 10.
    Zhu FC, Hou LH, Li JX, et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet. 2015;385:2272–9.CrossRefGoogle Scholar
  11. 11.
    Li JX, Hou LH, Meng FY, et al. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Glob Health. 2017;5:e324–34.CrossRefGoogle Scholar
  12. 12.
    Wu L, Zhang Z, Gao H, et al. Open-label phase I clinical trial of Ad5-EBOV in Africans in China. Hum Vacc Immunother. 2017;13:2078–85.CrossRefGoogle Scholar
  13. 13.
    Zhu FC, Wurie AH, Hou LH, et al. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2017;389:621–8.CrossRefGoogle Scholar
  14. 14.
    Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe—preliminary report. N Engl J Med. 2016;374:1647–60.CrossRefGoogle Scholar
  15. 15.
    Regules JA, Beigel JH, Paolino KM, et al. A recombinant vesicular stomatitis virus Ebola vaccine—preliminary report. N Engl J Med. 2017;376:330–41.CrossRefGoogle Scholar
  16. 16.
    Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;386:857–66.CrossRefGoogle Scholar
  17. 17.
    Henao-Restrepo AM, Camacho A, Longini IM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet. 2017;389:505–18.CrossRefGoogle Scholar
  18. 18.
    Huttner A, Dayer JA, Yerly S, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis. 2015;15:1156–66.CrossRefGoogle Scholar
  19. 19.
    Halperin SA, Arribas JR, Rupp R, et al. Six-month safety data of recombinant vesicular stomatitis virus-zaire Ebola virus envelope glycoprotein vaccine in a phase 3 double-blind, placebo-controlled randomized study in healthy adults. J Infect Dis. 2017;215:1789–98.CrossRefGoogle Scholar
  20. 20.
    ElSherif MS, Brown C, MacKinnon-Cameron D, et al. Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial. CMAJ. 2017;189:E819–27.CrossRefGoogle Scholar
  21. 21.
    Heppner DG Jr, Kemp TL, Martin BK, et al. Safety and immunogenicity of the rVSVG-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Lancet Infect Dis. 2017;17:854–66.CrossRefGoogle Scholar
  22. 22.
    Agnandji ST, Fernandes JF, Bache EB, et al. Safety and immunogenicity of rVSVDeltaG-ZEBOV-GP Ebola vaccine in adults and children in Lambarene, Gabon: a phase I randomised trial. PLoS Med. 2017;14:e1002402.CrossRefGoogle Scholar
  23. 23.
    Kennedy SB, Bolay F, Kieh M, et al. Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia. N Engl J Med. 2017;377:1438–47.CrossRefGoogle Scholar
  24. 24.
    Dolzhikova IV, Zubkova OV, Tukhvatulin AI, et al. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: an open phase I/II trial in healthy adults in Russia. Hum Vacc Immunother. 2017;13:613–20.CrossRefGoogle Scholar
  25. 25.
    Ledgerwood JE, DeZure AD, Stanley DA, et al. Chimpanzee adenovirus vector Ebola vaccine—preliminary report. N Engl J Med. 2015;373:775–6.CrossRefGoogle Scholar
  26. 26.
    Tapia MD, Sow SO, Lyke KE, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2016;16:31–42.CrossRefGoogle Scholar
  27. 27.
    De Santis O, Audran R, Pothin E, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis. 2016;16:311–20.CrossRefGoogle Scholar
  28. 28.
    Ewer K, Rampling T, Venkatraman N, et al. A monovalent Chimpanzee adenovirus Ebola vaccine boosted with MVA. N Engl J Med. 2016;374:1635–46.CrossRefGoogle Scholar
  29. 29.
    Milligan ID, Gibani MM, Sewell R, et al. Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial. JAMA J Am Med Assoc. 2016;315:1610–23.CrossRefGoogle Scholar
  30. 30.
    Winslow RL, Milligan ID, Voysey M, et al. Immune responses to novel adenovirus type 26 and modified vaccinia virus Ankara-vectored Ebola vaccines at 1 year. JAMA J Am Med Assoc. 2017;317:1075–7.CrossRefGoogle Scholar
  31. 31.
    World Health Organization. Meeting of the strategic advisory group of experts on immunization, April 2017—conclusions and recommendations. Wkly Epidemiol Rec. 2017;92:301–20.Google Scholar
  32. 32.
    Centers for Disease Control and Prevention. 2018 Eastern Democratic Republic of the Congo. https://www.cdc.gov/vhf/ebola/outbreaks/drc/2018-august.html.
  33. 33.
    Medcins sans Frontieres. DRC 2018 Ebola outbreaks—Crisis update November 2018. https://www.msf.org/drc-2018-ebola-outbreak-crisis-update.
  34. 34.
    World Health Organization. Ebola virus disease—Democratic Republic of the Congo. http://www.who.int/csr/don/14-september-2018-ebola-drc/en/.
  35. 35.
    World Health Organization. Ebola situation report, 13 November 2018. Geneva: World Health Organization; 2018.Google Scholar
  36. 36.
  37. 37.
    Huttner A, Agnandji ST, Combescure C, et al. Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study. Lancet Infect Dis. 2018;18:738–48.CrossRefGoogle Scholar
  38. 38.
    Huttner A, Siegrist CA. Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know? Expert Rev Vacc. 2018;17:1105–10.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Laboratory of Virology, Division of Intramural ResearchNational Institute of Allergy and Infectious Diseases, National Institutes of HealthHamiltonUSA
  2. 2.Galveston National Laboratory, and Department of Microbiology and ImmunologyUniversity of Texas Medical BranchGalvestonUSA

Personalised recommendations